drugset / Trial / NCT03915626
Effect of Heat on Rivastigmine TDS Products
Phase 0
Completed
7 enrolled
University of Maryland, Baltimore
Food and Drug Administration (FDA) · collab
Non-randomizedCrossoverOpen-labelOther
Summary
This research study is designed to measure the amount of medicine in blood over time after the patch is placed on the skin with and without external heat application.
Timeline
- Start
- 2019-10-04
- Primary completion
- 2021-05-04
- Completion
- 2021-05-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivastigmine | Small molecule | 4.6 mg | Other |
Indications
No indication recorded.